Originally founded in 2003 to develop novel, high performance drug discovery screening systems by fusing microsystems engineering with cell biology, Cellectricon was spun out of Chalmers University of Technology, Sweden.
From a broad IP portfolio and profound expertise in microfluidics and electrophysiology, we rapidly developed several highly innovative technology platforms that were successfully launched to the market. Over the years, we developed a substantial Client base consisting of large pharmaceutical and biotech companies as well as leading academic institutions.
With the change in drug discovery paradigms towards one of outsourcing of specialized services, we decided in 2012 to offer access to our technology platform with a services-based offering. With an initial focus on chronic pain drug discovery, our experienced neurobiologist team provided fully collaborative assay development and phenotypic primary cell screening to leading pharmaceutical companies. We quickly obtained commercial traction and in 2014 we decided to withdraw from all direct product sales activities.
Today, we take the next step in our journey. We, and several of our Clients, have identified unique opportunities for our discovery platform in neurodegenerative disease discovery and research. Since 2016 we have explored these concepts and further refined our platform to enable drug discovery campaigns focused on previously unidentified targets and thus provide an opportunity for the development of highly differentiated therapeutics for several neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases.
Based in Sweden, Cellectricon AB is a privately held company. The main shareholders are Ägir Invest, Dunross & Co., together with employees and seed investors.